Kiniksa Pharmaceuticals
KNSA
92 hedge funds and large institutions have $290M invested in Kiniksa Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 37 increasing their positions, 26 reducing their positions, and 9 closing their positions.
114% more call options, than puts
Call options by funds: $3.32M | Put options by funds: $1.55M
42% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 26
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.96% less ownership
Funds ownership: 90.27% → 87.3% (-3%)
4% less funds holding
Funds holding: 96 → 92 (-4)
5% less capital invested
Capital invested by funds: $306M → $290M (-$15.5M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.88M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$3.11M |
| 3 |
Walleye Capital
New York
|
+$1.81M |
| 4 |
Morgan Stanley
New York
|
+$1.75M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.78M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.28M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$3.01M |
| 4 |
Goldman Sachs
New York
|
-$2.82M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.78M |
KNSA Hedge Fund Activity: Q2 2022 in Review
92 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q2 2022, worth a combined $290M — down 5.1% from $306M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of KNSA and 6 opened new positions — a net loss of 3 holders — while 26 trimmed existing stakes and 37 added.
The largest buyer was Rubric Capital Management (New York), opening a new position worth an estimated $4.88M. The largest seller was Millennium Management, cutting an estimated $6.78M.
- 92 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q2 2022, down from 96 in Q1 2022.
- Funds reported $290M of Kiniksa Pharmaceuticals stock for Q2 2022, down 5.1% quarter-over-quarter.
- 6 funds opened new Kiniksa Pharmaceuticals positions in Q2 2022 and 9 closed out, a net change of -3 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q2 2022 was Rubric Capital Management (New York), an estimated $4.88M added.
- The largest Kiniksa Pharmaceuticals seller in Q2 2022 was Millennium Management, an estimated $6.78M sold.
Based on aggregated 13F filings for Q2 2022.